The Protein Interactions Expert


A new incredible interaction map of chromosome 21 proteins :

Evry, France - January 22

“Chr21 protein-protein interactions: enrichment in products involved in intellectual disabilities, autism and Late Onset Alzheimer Disease” on BioRxiv.

More than 1500 interactionswere identified by Yeast two-hybrid with their interacting domains. All the data will be published on intact as well.

This article brings new knowledge on trisomie21 and brain functions.

This Massive Scientific Program was financed by Jerome Lejeune Foundation


Meet us at EMBL Conference - Expanding the Druggable Proteome with Chemical Biology

Heidelberg, Germany - 5 - 7 Feb

Meet us at the EMBL Conference - Expanding the Druggable Proteome with Chemical Biologyin Heidelberg, Germany from February 5th to 7th , 2020.

This conference will bring together academic and industrial scientists with interests in chemical biology, chemogenomic libraries, pharmacology, medicinal chemistry and bioinformatics

Dr. Marie-Edith Gourdel, Director of Chemistry and Söhnke Kühnhold Business Development Manager will attend this event. They will be happy to meet you and present our target deconvolution services, ULTImate YChemH, and ULTImate Y2H+Chem.

Feel free to contact us to arrange a meeting with our team!


Add to Calendar 02-05-2020 00:00:00 02-07-2020 00:00:00 40 Meet us at EMBL Conference - Expanding the Druggable Proteome with Chemical Biology Dr. Marie-Edith Gourdel and Söhnke Kühnhold will attend this event and will be happy to meet you to discuss your project. Heidelberg, Germany embl false MM/DD/YYYY

Best Wishes for 2020

Evry, France - 03 January

Warmest season's greetings and best wishes for 2020 from everyone at Hybrigenics Services! 

Hybrigenics Services is fully independent from Hybrigenics Pharma

Evry, France - October 16, 2019

Please note that Hybrigenics Services ( and Hybrigenics Pharma ( have been two financially independent companies since January 2017 despite keeping similar names. Our activities are completely distinct and our operations entirely separate.

Hybrigenics Pharma announced on October 23, 2018 that the clinical development of its only drug candidate was discontinued for lack of efficacy. The winding-up of the company was suspended in January, 2019 when Hybrigenics Pharma received a takeover offer. On October 15, 2019 Hybrigenics Pharma announced its takeover by DMS Group with immediate effect.

None of this affects Hybrigenics Services in any way, nor the research we conduct for our clients and partners. We regret the confusion this might cause.

We thank investigators and companies across the world for their trust and continued interest in our services.

Old news

Back to Top